Effect of glucocerebrosidase on human bone marrow multipotent mesenchymal stromal
Open Access
- 25 November 2024
- journal article
- research article
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (3) , 330-343-343
Abstract
Introduction. During enzyme replacement therapy in patients with Gaucher disease (GD) with recombinant glucocerebrosidase (GCase), regression of bone manifestations is possible, but with prolonged therapy osteonecrosis may occur. These changes may be due to impaired differentiation of multipotent mesenchymal stromal cells (MSCs).Aim: to study changes in the MSCs of healthy donors and a patient with GD when cultured in the presence of GCase.Material and methods. MSCs were isolated from the bone marrow of 17 healthy donors and a female patient with GD by a standard method and cultured in the presence of various concentrations of GCase after the second passage from 2 to 7 weeks. Cell proliferation and the ability to differentiate were analyzed, including after induction. The assessment was carried out by differential staining, elution, and expression of differentiation marker genes by real-time PCR.Results. Low concentrations of recombinant GCase (0.25–1.5 U/ml) did not affect the proliferative activity of MSCs. Prolonged cultivation of MSCs in the presence of low doses of GCase led to a change in the differentiation potential of these cells in the direction of adipogenesis. Concentrations of GCase of 3–5 U/ml inhibited the proliferation of MSCs and caused significant changes in cell differentiation. High doses of the enzyme (7–10 U/ml) had a cytotoxic effect and led to cell death within one passage. The proliferative and differentiation potential of the MSCs of a patient with GD differed significantly from the cells of healthy donors in all the parameters studied.Conclusion. The cultivation of donor MSCs in the presence of recombinant GCase alters the proliferation and differentiation potential of these cells. These changes depend on the dose of the enzyme in the medium and the duration of cultivation.Keywords
This publication has 25 references indexed in Scilit:
- Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesisMolecular Genetics and Metabolism, 2020
- Bone Marrow Multipotent Mesenchymal Stromal Cells in Patients with Diffuse Large B-Cell LymphomaBulletin of Experimental Biology and Medicine, 2019
- Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher diseaseMolecular Genetics and Metabolism, 2018
- HypophosphatasiaMetabolism, 2018
- Impact of lysosomal storage disorders on biology of mesenchymal stem cells: Evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha‐galactosidase A (GLA) enzymesJournal of Cellular Physiology, 2017
- Management of Bone Disease in Gaucher Disease Type 1: Clinical PracticeAdvances in Therapy, 2014
- Velaglucerase Alfa for the Management of Type 1 Gaucher DiseaseClinical Therapeutics, 2012
- Enzyme replacement therapy for mild patients with Gaucher diseaseAmerican Journal of Hematology, 2009
- A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated® human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher diseaseBlood Cells, Molecules, and Diseases, 2007
- Prevalence of Lysosomal Storage DisordersJAMA, 1999